
The American Thoracic Society recently released a thoughtful, forward-thinking statement outlining a research agenda for precision medicine in sepsis and acute respiratory distress syndrome (ARDS). The statement draws attention to the highly variable treatment responsiveness problem in these heterogeneous syndromes. It proposes many promising solutions to address this problem, focusing on enhanced molecular phenotyping and novel trial designs. This approach is predicated on an overarching hypothesis that the molecular contents of biospecimens contain the key to unlocking patient heterogeneity for precision-guided therapy for sepsis and ARDS.
Like
Save
Share